Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.

CAS  PubMed  Google Scholar 

Cancer Today [Internet]. [cited 2019 Dec 29]. Available from: https://gco.iarc.fr/today/home

Getz G, Gabriel SB, Cibulskis K, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.

CAS  Google Scholar 

Shah SN, Hile SE, Eckert KA. Defective mismatch repair, microsatellite mutation bias, and variability in clinical cancer phenotypes. Cancer Res. 2010;70(2):431–5.

CAS  PubMed  PubMed Central  Google Scholar 

Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12–39.

PubMed  Google Scholar 

Heong V, Ngoi N, Peng Tan DS. Update on immune checkpoint inhibitors in gynecological cancers. J Gynecol Oncol. 2017;28(2):1–19.

Google Scholar 

Tangjitgamol S, Kittisiam T, Tanvanich S. Prevalence and prognostic role of mismatch repair gene defect in endometrial cancer patients. Tumor Biol. 2017;39(9):1010428317725834.

Google Scholar 

Rekhi B, Menon S, Deodhar KK, et al. Annals of diagnostic pathology clinicopathological features of 50 mismatch repair ( MMR ) -de fi cient endometrial carcinomas, tested by immunohistochemistry: A single institutional feasibility study, India. Ann Diagn Pathol. 2020;47:151558. https://doi.org/10.1016/j.anndiagpath.2020.151558.

Article  PubMed  Google Scholar 

Kumar P, Gupta P, Gupta N, et al. Evaluation of DNA mismatch repair protein deficiency in primary endometrial carcinoma. J Gynecol Surg. 2019;35(3):177–83.

Google Scholar 

Sharma A, Kamboj M, Panaych A, et al. Assessment of mismatch repair protein expression by immunohistochemistry in endometrial carcinomas with clinicopathological correlation: A study from Indian tertiary cancer care centre. Int J Mol Immuno Oncol. 2020;5(3):101–7.

Google Scholar 

Jain E, Prasad S, Dhar A, et al. The utility of evaluating mismatch repair proteins in endometrial carcinoma: an experience from a tertiary referral centre in North India. Pathologica. 2021;113(2):115–20.

PubMed  PubMed Central  Google Scholar 

Mendiola M, Heredia-Soto V, Ruz-Caracuel I, et al. Comparison of methods for testing mismatch repair status in endometrial cancer. Int J Mol Sci. 2023;24(19):14468.

CAS  PubMed  PubMed Central  Google Scholar 

Streel S, Salmon A, Dheur A, et al. Diagnostic performance of immunohistochemistry compared to molecular techniques for microsatellite instability and p53 mutation detection in endometrial cancer. Int J Mol Sci. 2023;24(5):4866.

CAS  PubMed  PubMed Central  Google Scholar 

Arabi H, Guan H, Kumar S, et al. Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma. Gynecol Oncol. 2009;113(2):153–8. https://doi.org/10.1016/j.ygyno.2009.02.004.

Article  CAS  PubMed  Google Scholar 

WHO_FGT_2020_5th Edition.pdf.

McCourt CK, Mutch DG, Gibb RK, et al. Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. Gynecol Oncol. 2007;104(3):535–9.

PubMed  Google Scholar 

Joehlin-Price AS, Perrino CM, Stephens J, et al. Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables. Gynecol Oncol. 2014;133(1):43–7. https://doi.org/10.1016/j.ygyno.2014.01.017.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woo YL, Cheah PL, Shahruddin SI, et al. The immunohistochemistry signature of mismatch repair (MMR) proteins in a multiethnic asian cohort with endometrial carcinoma. Int J Gynecol Pathol. 2014;33(6):554–9.

CAS  PubMed  Google Scholar 

Shikama A, Minaguchi T, Matsumoto K, et al. Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas. Gynecol Oncol. 2016;140(2):226–33. https://doi.org/10.1016/j.ygyno.2015.11.032.

Article  CAS  PubMed  Google Scholar 

Kim SR, Pina A, Albert A, et al. Does MMR status in endometrial cancer influence response to adjuvant therapy? Gynecol Oncol. 2018;151(1):76–81. https://doi.org/10.1016/j.ygyno.2018.08.020.

Article  CAS  PubMed  Google Scholar 

Orbegoso Aguilar CMA, Vroobel K, Attygalle A, et al. MMR deficiency(d) in an unselected cohort of endometrial cancer (EC) patients, the Royal Marsden experience. Ann Oncol. 2018;29:ix79. https://doi.org/10.1093/annonc/mdy436.

Article  Google Scholar 

Pasanen A, Loukovaara M, Bützow R. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma. Mod Pathol. 2020;33(7):1443–52. https://doi.org/10.1038/s41379-020-0501-8.

Article  CAS  PubMed  Google Scholar 

Leon-Castillo A, De Boer SM, Powell ME, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol. 2020;38(29):3388–97.

CAS  PubMed  PubMed Central  Google Scholar 

Jumaah AS, Al-Haddad HS, Salem MM, et al. Mismatch repair deficiency and clinicopathological characteristics in endometrial carcinoma: a systematic review and meta-analysis. J Pathol Transl Med. 2021;55(3):202–11.

PubMed  PubMed Central  Google Scholar 

Kolehmainen A, Pasanen A, Tuomi T, et al. Clinical factors as prognostic variables among molecular subgroups of endometrial cancer. PLoS ONE. 2020;15:1–12.

Google Scholar 

Kato M, Takano M, Miyamoto M, et al. DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers. J Gynecol Oncol. 2015;26(1):40–5.

CAS  PubMed  PubMed Central  Google Scholar 

Gordhandas S, Kahn RM, Gamble C, et al. Clinicopathologic features of endometrial cancer with mismatch repair deficiency. Ecancermedicalscience. 2020;14:1–16.

Google Scholar 

Pina A, Wolber R, McAlpine JN, et al. Endometrial cancer presentation and outcomes based on mismatch repair protein expression from a population-based study. Int J Gynecol Cancer. 2018;28(8):1624–30.

PubMed  Google Scholar 

McMeekin DS, Tritchler DL, Cohn DE, et al. Clinicopathologic significance of mismatch repair defects in endometrial cancer: An NRG oncology/gynecologic oncology group study. J Clin Oncol. 2016;34(25):3062–8.

CAS  PubMed  PubMed Central  Google Scholar